Alnylam Pharmaceuticals said this week that it has granted Sylentis, a Spanish developer of RNAi drugs, a non-exclusive option to license certain of its RNAi-related intellectual property.

According to Alnylam, the option gives Sylentis the chance to develop an siRNA-based treatment for an undisclosed glaucoma target using Alnylam's IP.

Upon execution of the option, Alnylam would receive upfront and milestone payments, and royalties on product sales. Additional terms were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Sep
12
Sponsored by
PerkinElmer

This webinar will cover recent advances in the use of CRISPR for generating animal models and cell lines.